Armata Pharmaceuticals (NYSE:ARMP) is poised to become the first company to advance a bacteriophage candidate into a Phase 3 clinical trial, following a positive End-of-Phase 2 (EOP2) response from the U.S. Food and Drug Administration (FDA).
The regulator confirmed that data from Armata’s diSArm study support the transition of its intravenous lead candidate, AP-SA02, into a pivotal superiority study for complicated Staphylococcus aureus bacteremia (SAB).
The upcoming Phase 3 trial, slated to begin in the second half of 2026, will evaluate whether AP-SA02 is superior to the current standard of care—typically heavy-duty antibiotics like vancomycin or daptomycin.
The study will focus on two primary endpoints: clinical success at the end of antibiotic therapy and sustained recovery at Day 28.
The FDA’s written response provided a comprehensive roadmap for the program, offering guidance on study design, Chemistry, Manufacturing, and Controls (CMC), and expectations for an eventual Biologics License Application (BLA).
Furthermore, the agency encouraged Armata to apply for Qualified Infectious Disease Product (QIDP) designation.
Armata confirmed it has already submitted the QIDP request.
If granted, the designation—created under the GAIN Act—would provide AP-SA02 with high-value incentives, including eligibility for Fast Track status, Priority Review, and an additional five years of market exclusivity upon approval.
The move to Phase 3 follows late-breaking data presented at IDWeek 2025, which showed that AP-SA02 significantly improved outcomes in patients with complicated SAB.